Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Acquisitions (2020 - 2024)

Historic Acquisitions for Haemonetics (HAE) over the last 9 years, with Q3 2024 value amounting to $1.8 million.

  • Haemonetics' Acquisitions changed N/A to $1.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year decrease of 9955.34%. This contributed to the annual value of $150.9 million for FY2025, which is 3811.57% down from last year.
  • As of Q3 2024, Haemonetics' Acquisitions stood at $1.8 million.
  • In the past 5 years, Haemonetics' Acquisitions ranged from a high of $418.2 million in Q2 2021 and a low of $1.8 million during Q3 2024
  • Its 5-year average for Acquisitions is $119.3 million, with a median of $16.6 million in 2020.
  • As far as peak fluctuations go, Haemonetics' Acquisitions crashed by 8494.52% in 2021, and later surged by 1400.0% in 2022.
  • Over the past 5 years, Haemonetics' Acquisitions (Quarter) stood at $16.6 million in 2020, then crashed by 84.95% to $2.5 million in 2021, then increased by 14.0% to $2.8 million in 2022, then surged by 8456.21% to $243.9 million in 2023, then crashed by 99.28% to $1.8 million in 2024.
  • Its Acquisitions stands at $1.8 million for Q3 2024, versus $149.2 million for Q2 2024 and $243.9 million for Q4 2023.